959801-07-1

Upstream product

• 608-31-1 2,6-Dichloroaniline 
• 38491-47-3 ethyl 4-methylpent-2-ynoate 
• 959800-65-8 3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazole-4-carboxylic acid ethyl ester 
• 959800-67-0 [3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-yl]-methanol 
• 80866-47-3 methyl 4-methylpent-2-ynoate 
• 57341-09-0 1-azido-2,6-dichlorobenzene 
• 550377-89-4 4-{[tert-butyl(dimethyl)silyl]oxy}-2-chlorobenzaldehyde 
• 56962-11-9 2-chloro-4-hydroxybenzaldehyde 
• 959801-05-9 2-chloro-4-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-benzaldehyde 

Relevant academic research and scientific papers

Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists

The farnesoid X receptor (FXR) may play a crucial role in a number of metabolic diseases and, as such, could potentially serve as a target for the development of therapeutics as a treatment for those diseases. Previous work has described GW4064 as an FXR

COMPOUNDS AND METHODS FOR MODULATING FXR

Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.